• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Xintela

0.19 SEK+0.80 %24.7. klo 18.29
Less than 1K followers

XINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.80 %
-1.04 %
-30.91 %
-40.44 %
-33.10 %
-51.39 %
-34.13 %
-86.24 %
-91.70 %

Xintela operates in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes on the surface of cells, which enables the identification of stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.

Read more
Market cap
163.64M SEK
Turnover
86.28K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8.
2026

Interim report Q2'26

27.11.
2026

Interim report Q3'26

26.2.
2027

Annual report '26

Third party research04.06.2026 klo 09.58

Xintela: Completing another phase I/IIa study - VH Corp

• Considering the alternatives in wound treatment • Discussions about investigator-initiated studies continue • We keep our fair value at SEK 1.04 per share On the day of the Q1 report, Xintela announced positive results of its phase I/IIa study of XSTEM...

Xintela
Press release04.06.2026 klo 09.00

Västra Hamnen Market Focus: Xintela: Completing another phase I/IIa study

Xintela
Regulatory press release29.05.2026 klo 15.25

Xintela AB Interim Report January - March 2026

Xintela

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release29.05.2026 klo 11.00

Xintela reports safety results from the XSTEM clinical study in difficult-to-heal venous leg ulcers

Xintela
Regulatory press release28.05.2026 klo 14.00

Xintela AB changes Certified Adviser to Västra Hamnen Corporate Finance AB

Xintela
Press release12.05.2026 klo 14.15

Xintela granted patent in Japan for XSTEM® treatment of acute respiratory distress syndrome (ARDS)

Xintela
Regulatory press release30.04.2026 klo 08.50

Xintela AB publishes Annual Report 2025

Xintela
Press release14.04.2026 klo 14.05

Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

Xintela
Press release14.04.2026 klo 00.15

Xintela publication on EQSTEM treatment of horses in a preclinical osteoarthritis study awarded best basic science paper

Xintela
Third party research03.03.2026 klo 10.21

Xintela: Moving forward with XSTEM - VH Corp

* Professor Hall comments on the XSTEM study results * In discussions with investigator-initiated studies * We keep our fair value of SEl 1.04 per share Xintela’s year-end report did not reveal any substantial surprises. The recent rights issue and loan...

Xintela
Press release03.03.2026 klo 10.15

Västra Hamnen Market Focus: Xintela: Moving forward with XSTEM

Xintela
Regulatory press release27.02.2026 klo 08.00

Xintela AB Year-end Report 2025

Xintela
Press release17.02.2026 klo 12.07

Västra Hamnen Market Focus: Professor Hall comments on Xintela's study results

Xintela
Press release13.02.2026 klo 15.50

Xintela completes clinical study with XSTEM in difficult-to-heal leg ulcers

Xintela
Third party research12.12.2025 klo 12.17

Xintela: Extending the financial runway - VH Corp

* The rights issue added MSEK 42 before loan offset * Fenja Capital II provides loan facility of MSEK 20 * After dilution, our fair value amounts to SEK 1.04 (1.28) per share Xintela’s recent rights issue was subscribed to 58 per cent, corresponding ...

Xintela
Press release12.12.2025 klo 11.49

Västra Hamnen Market Focus: Xintela: Extending the financial runway

Xintela
Third party research12.11.2025 klo 11.20

Xintela: Focus on study results and financing - VH Corp

• Final study results support XSTEM’s disease-modifying potential in OA • Rights issue of MSEK 72.8 announced at SEK 0.26 per share • Q&A with CEO Evy Lundgren Åkerlund on the new Targinta collaboration Xintela released its Q3 report on November 4 instead...

Xintela
Press release12.11.2025 klo 11.15

Västra Hamnen Market Focus: Xintela: Focus on study results and financing

Xintela
Regulatory press release04.11.2025 klo 19.05

Xintela AB Interim Report January - September 2025

Xintela
Press release30.10.2025 klo 09.15

Last patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers

Xintela